| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01205217 Details | 2017-06-07 Interventional | 2 | 0 | Cyclophosphamid… Epirubicin Lapatinib Paclitaxel Trastuzumab Breast Neoplasm… Neoplasms, Brea… | Data presented at SABCS 2010 showing that dual blockade is superior to monotherapy - | |||
| NCT01166724 Details | 2017-06-07 Interventional | 3 | 12 | Sirolimus Tacrolimus Kidney Transpla… | Collaborator stopped study Early termination; Sponsor discontinued the study for corporate reasons. No data analyzed. | |||
| NCT00632203 Details | 2017-06-07 Interventional | 2 | [1 Refs] | 53 | Temozolomide Carcinoma Carcinoma, Larg… Carcinoma, Non-… Carcinoma, Squa… Adenocarcinoma | - The interpretation of the study results should be taken with caution because of the small sample size due to early termination. | ||
| NCT00604968 Details | 2017-06-07 Interventional | 4 | [1 Refs] | 25 | Doxorubicin Liposomal doxor… Breast Neoplasm… | - - | ||
| NCT02125643 Details | 2017-06-05 Interventional | 1 | [7 Refs] | 3 | Caffeine Healthy | Protocol was deem insufficient to answer research question - | ||
| NCT01972516 Details | 2017-06-05 Interventional | 2 | 4 | Tivozanib Fallopian Tube … Ovarian Neoplas… Fallopian Tube … Ovarian Cancer Primary Periton… | due to slow accrual Terminated early due to low accrual. | |||
| NCT00637494 Details | 2017-06-05 Interventional | 3 | 292 | Mifepristone Depression Depressive Diso… Depressive Diso… Mental Disorder… Psychotic Disor… Psychosis Psychotic Depre… Severe Major De… | DRC recommended stopping study as it had missed its primary endpoint - | |||
| NCT01019707 Details | 2017-06-02 Interventional | 1 | 6 | Atomoxetine Hyd… Methamphetamine… Methamphetamine… | End in funding Early termination leading to small number of subject analyzed | |||
| NCT01712399 Details | 2017-06-01 Interventional | 2 | 409 | Mavrilimumab Arthritis Arthritis, Rheu… Rheumatoid Arth… | The study was terminated after approximately 3 years due to future clinical development plans,
including ethical considerations. The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations. | |||
| NCT00986947 Details | 2017-06-01 Interventional | 2 | 20 | Rituximab Renal Insuffici… Kidney Failure | - - | |||
| NCT00787787 Details | 2017-06-01 Interventional | 2 | 41 | Capecitabine Sunitinib Carcinoma Carcinoma, Hepa… Liver Neoplasms Adult Primary H… Advanced Adult … Localized Unres… Recurrent Adult… | - - | |||
| NCT00708721 Details | 2017-06-01 Interventional | 1/2 | 11 | Clofarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Cancer Chronic Myelomo… | Data analysis revealed sufficient data for safety and efficacy - | |||
| NCT00673153 Details | 2017-06-01 Interventional | 2 | 31 | Calicheamicins Gemtuzumab Vorinostat Leukemia Leukemia, Eryth… Leukemia, Megak… Leukemia, Monoc… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Adult Acute Meg… Adult Acute Min… Adult Acute Mon… Adult Acute Mon… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Acute Mye… Adult Erythrole… Adult Pure Eryt… Untreated Adult… | - - | |||
| NCT02648633 Details | 2017-05-31 Interventional | 1 | 4 | Nivolumab Valproic Acid Glioblastoma | The pharmaceutical company (BMS) would no longer provide nivolumab for the study, so the study
was terminated early. - | |||
| NCT01729338 Details | 2017-05-31 Interventional | 2 | 17 | Bortezomib Cyclophosphamid… Lenalidomide Multiple Myelom… Neoplasms, Plas… | - - | |||
| NCT01310855 2010-021531-13 Details | 2017-05-31 Interventional | 2 | 38 | Cediranib Gefitinib Glioblastoma | closed to recruitment early due to AstraZeneca not developing cediranib further - | |||
| NCT01201213 Details | 2017-05-31 Interventional | 4 | 14 | Anesthetics Anesthetics, Lo… Pain | Audit pre regulatory inspection - | |||
| NCT02856568 Details | 2017-05-30 Interventional | 1 | 0 | Cisplatin Gemcitabine Ricolinostat Bile Duct Neopl… Carcinoma, Duct… Cholangiocarcin… Klatskin Tumor Non-Resectable … Recurrent Chola… Stage III Extra… Stage III Intra… Stage IIIA Hila… Stage IIIB Hila… Stage IVA Extra… Stage IVA Hilar… Stage IVA Intra… Stage IVB Extra… Stage IVB Hilar… Stage IVB Intra… Unresectable Ex… | Site dropped study - | |||
| NCT02538081 Details | 2017-05-30 Interventional | 1/2 | 0 | Risperidone Schizophrenia | Withdrawn - | |||
| NCT02259348 Details | 2017-05-30 Interventional | 2 | 12 | Aldesleukin Cyclophosphamid… Fludarabine Fludarabine pho… Interleukin-2 Mechlorethamine Melphalan Rituximab Thiotepa Hematologic Neo… Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma, Non-H… Myelodysplastic… Neoplasms Precursor Cell … Preleukemia Sarcoma, Myeloi… Acute Lymphobla… Acute Myeloid L… Chronic Myeloge… Juvenile Myelom… Myelodysplastic… Myeloid Sarcoma Non-Hodgkin Lym… | Investigator's decision. The trial was terminated early due to investigator's decision. |